Longeveron Inc. (LGVN)
NASDAQ: LGVN · IEX Real-Time Price · USD
1.280
-0.010 (-0.78%)
May 17, 2024, 4:00 PM EDT - Market closed
Longeveron Revenue
Longeveron had revenue of $978.00K in the twelve months ending March 31, 2024, down -13.53% year-over-year. Revenue in the quarter ending March 31, 2024 was $548.00K with 96.42% year-over-year growth. In the year 2023, Longeveron had annual revenue of $709.00K, a decrease of -41.98%.
Revenue (ttm)
$978.00K
Revenue Growth
-13.53%
P/S Ratio
8.22
Revenue / Employee
$42,522
Employees
23
Market Cap
8.03M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 30, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Integrated Sciences | 13.66M |
| NeuroMetrix | 5.27M |
| Notable Labs | 311.00K |
| BioRestorative Therapies | 145.80K |
| Vaccinex | 124.00K |
LGVN News
- 4 days ago - Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - Longeveron Announces Board of Directors Planned Transitions - GlobeNewsWire
- 16 days ago - Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 - GlobeNewsWire
- 23 days ago - Longeveron to Present at the Planet MicroCap Showcase - GlobeNewsWire
- 4 weeks ago - Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering - GlobeNewsWire
- 4 weeks ago - Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds - GlobeNewsWire
- 4 weeks ago - Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC) - GlobeNewsWire
- 5 weeks ago - Longeveron Announces Closing of $5.2 Million Public Offering - GlobeNewsWire